Assembly Biosciences (ASMB) vs Gyre Therapeutics (GYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Assembly Biosciences (ASMB) has outperformed Gyre Therapeutics (GYRE) over the past year, losing 42.4% versus a loss of 44.2%. Over five years, ASMB leads with a -21.3% price change compared with -77.5% for GYRE. Gyre Therapeutics is the larger company by market cap ($460.8 million vs $454.4 million), about 1.0 times the size, while Assembly Biosciences is growing revenue faster (+153.5% vs +10.2%).
Gyre Therapeutics converts more of its revenue into profit, with a net margin of 8.5% versus -8.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | GYRE |
|---|---|---|
| Share price | $22.19 | $4.21 |
| Market cap | $454.39M | $460.79M |
| 1-day change | -1.38% | -6.86% |
| YTD return | -34.75% | -40.37% |
| 1-year return | -42.36% | -44.24% |
| 5-year return | -21.31% | -77.55% |
| P/E ratio (TTM) | 29.59 | — |
| Forward P/E | — | 70.17 |
| EPS (TTM) | $0.75 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $72.30M | $116.59M |
| Revenue growth (YoY) | +153.52% | +10.24% |
| Net income (latest FY) | $-6.12M | $9.88M |
| Gross margin | — | 95.35% |
| Operating margin | -16.76% | 9.85% |
| Net margin | -8.47% | 8.47% |
| 52-week high | $39.65 | $9.14 |
| 52-week low | $19.20 | $3.97 |
| Distance from 52-week high | -44.04% | -53.94% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +130.73% | +343.47% |
| Average volume | 309.38K | 181.04K |
| Shares outstanding | 20.48M | 109.45M |
| Employees | 73 | 625 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Gyre Therapeutics is more profitable, keeping 8.5 cents of every revenue dollar as net income versus -8.5 cents for Assembly Biosciences.
- Assembly Biosciences grew revenue faster in its latest fiscal year (+153.52% vs +10.24%).
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
ASMB vs GYRE FAQ
Which is bigger, Assembly Biosciences or Gyre Therapeutics?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $460.79M compared with $454.39M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ASMB or GYRE?
ASMB returned -42.36% over the past 12 months, compared with -44.24% for GYRE (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Gyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.